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Abstract Group III metabotropic glutamate receptors (mGluRs)
serve as presynaptic receptors that mediate feedback inhibition of
glutamate release via a Ca2+/calmodulin (CaM)-dependent
mechanism. In vitro phosphorylation of mGluR7A by protein
kinase C (PKC) prevents its interaction with Ca2+/CaM. In
addition, activation of PKC leads to an inhibition of mGluR
signaling. Here, we demonstrate that disrupting CaM binding to
mGluR7A by PKC in vitro is due to phosphorylation of a highly
conserved serine residue, S862. We propose charge neutralization
of the CaM binding consensus sequence resulting from phos-
phorylation to constitute a general mechanism for the regulation
of presynaptic mGluR signaling. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Glutamate serves as a neurotransmitter at the vast majority
of excitatory synapses in the mammalian central nervous sys-
tem by activating two di¡erent receptor families, the gluta-
mate-gated cation channels forming ‘ionotropic’ glutamate
receptors [1] and the G protein-coupled ‘metabotropic’ gluta-
mate receptors (mGluRs) [2]. While ionotropic glutamate re-
ceptors drive fast neurotransmission, synaptic stimulation of
mGluRs generates slower and longer lasting changes [2]. One
of the most prominent roles of mGluRs is to serve as presyn-
aptic auto-receptors that mediate feedback inhibition of glu-
tamate release in a wide variety of brain regions, including the
hippocampus, neocortex, spinal cord, cerebellum and olfac-
tory bulb. This inhibition is thought to result from G pro-
tein-driven down-regulation of the voltage-activated Ca2
channels that trigger the Ca2 in£ux necessary for synaptic
vesicle exocytosis [3^6].
At present, eight di¡erent members of the mGluR family
have been identi¢ed [2,7]. Based on sequence homologies,
pharmacological properties and intracellular transduction
pathways, mGluRs are classi¢ed into three distinct groups.
Groups I and II include mGluRs that are post- and presyn-
aptic, whereas group III encompasses receptors (mGluRs 4, 6,
7 and 8 and their splice variants) that have been shown to be
principally presynaptic [8]. In particular, mGluR7 was found
to be highly enriched at active zones in terminals of hippo-
campal pyramidal cells [9]. This selective localization and its
low a⁄nity for glutamate have led to the hypothesis that
mGluR7 functions as a low-pass ¢lter that inhibits synapses
that ¢re above certain frequencies [9]. Consistent with this view,
mGluR7 knockout mice show epileptic seizures at s 12 weeks
of age in addition to an impairment of amygdala-dependent
behavioral traits [10].
Many receptors including ion channels and G protein-
coupled receptors are known to be modulated by phosphory-
lation. Such modulations can result in desensitization as
shown for mGluR5 [11] or in a ¢ne-tuning of receptor signal-
ing as reported for mGluR1K [12]. For group III mGluRs, it
has been shown that phorbol ester treatment of hippocampal
slices reduces mGluR-mediated presynaptic inhibition [13].
Furthermore, we recently identi¢ed calmodulin (CaM) as an
essential coregulator of mGluR7A [6], one of two known
C-terminal splice variants of this receptor [14]. In vitro phos-
phorylation by protein kinase C (PKC) of the cytosolic
C-terminal region of mGluR7A prevents its interaction with
Ca2/CaM, and conversely this phosphorylation is inhibited
by CaM binding [15]. These data provide functional and bio-
chemical evidence that phosphorylation of the mGluR7A tail
regulates Ca2-dependent CaM binding and G protein activa-
tion.
In this study, we identify serine 862 in the cytosolic C-ter-
minus of mGluR7A as the only residue that is phosphorylated
by PKC in vitro, and show that this phosphorylation is pre-
vented by the presence of Ca2/CaM. In addition, we demon-
strate that all group III mGluRs except mGluR4B and
mGluR6 are similarly phosphorylated at a homologous site.
Our data thus raise the intriguing possibility that most group
III mGluRs are regulated in an antagonistic fashion by PKC
and Ca2/CaM.
2. Materials and methods
2.1. Expression and mutant constructs
cDNAs corresponding to the C-terminal regions of mGluR4A, -4B,
-7A, -7B, -8A, and -8B were generated by PCR on either mouse brain
cDNA (mouse genomic DNA for mGluR6), or full-length mGluR4B
cDNA (generous gift of S. Nakanishi), using procedures similar to
those described previously [6]. cDNA fragments were subcloned into
the EcoRI and SalI sites of pGEX-5X1 (Pharmacia) or pMal-c2 (New
England Biolabs) to generate glutathione S-transferase (GST) or mal-
tose binding protein (MBP) fusion constructs. Mutations were intro-
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 3 1 1 - 0
*Corresponding author. Fax: (49)-69-96769441.
E-mail: neurochemie@mpih-frankfurt.mpg.de
Abbreviations: CaM, calmodulin; GST, glutathione S-transferase;
MBP, maltose binding protein; mGluR, metabotropic glutamate
receptor; PKC, protein kinase C
FEBS 24745 2-4-01
FEBS 24745FEBS Letters 494 (2001) 60^63
duced into these fusion proteins by PCR using a triple PCR method
as described [16]. The constructs pGEX-7A-S1234A, pGEX-7A-
S123A, pGEX-7A-S234A, pGEX-7A-S134A, pGEX-7A-S124A (num-
bers indicate the predicted phosphorylation sites S862, S873, S877 and
S881, respectively), pGEX-7A-EEE (K864, A865 and V866 replaced
by glutamates), pGEX-7A-S862A and pGEX-N25 were generated us-
ing as template pGEX-7A which harbors the cytosolic tail domain of
mGluR7A [6]. The ¢rst 25 amino acids of the tail region of mGluR7A
in pGEX-N25 served as template for creating pGEX-N25-S862A and
pGEX-N25-S862E (see Fig. 2A for further details). All ampli¢cation
products were veri¢ed by automated DNA sequencing.
2.2. Bacterial expression and a⁄nity puri¢cation
Expression of GST and MBP fusion proteins in Escherichia coli
BL21 (Stratagene) was induced by adding 0.5 mM isopropyl-L-D-thio-
galactopyranoside (Applichem) for 5 h. After passage through a
French press, the 100 000Ug supernatants containing soluble protein
were kept frozen (380‡C) until use.
2.3. CaM binding assay
Soluble fractions of GST or MBP fusion proteins (0.25 Wg protein)
were incubated with 20 Wl of CaM-agarose beads (Sigma) for 2 h at
4‡C in 0.5 ml of binding bu¡er (20 mM Tris^HCl, pH 7.4, 100 mM
NaCl, protease inhibitor cocktail Complete0 (Boehringer-Mannheim)
and 0.2% (w/v) Triton X-100), containing either 2 mM CaCl2 or 5 mM
EGTA. The beads were then washed ¢ve times with 0.5 ml of the
corresponding bu¡er. Bound fusion proteins were eluted with SDS
sample bu¡er and resolved by 12% SDS^PAGE, followed by Coo-
massie staining.
2.4. Phosphorylation reactions
Soluble fractions of GST or MBP fusion proteins (0.25 Wg protein)
were incubated with 20 Wl of glutathione-Sepharose beads for 2 h at
4‡C followed by three washes, each in 0.5 ml of binding bu¡er. Bound
proteins were then incubated in 100 Wl phosphorylation bu¡er (50
mM 2-N-morpholinoethane-sulfonic acid (MES) pH 6.0, 12.5 mM
MgCl2, 1.25 mM EGTA, 0.125 mM [32P]Q-ATP (3000 cpm/pmol))
containing 10 ng of PKM (Boehringer Mannheim), the catalytic frag-
ment of PKC, at 30‡C for 2 h. Phosphorylated proteins were eluted
with SDS sample bu¡er and resolved by 12% SDS^PAGE. Dried gels
were exposed to Kodak BioMax MR-1 ¢lm (Sigma) for 2^4 h.
3. Results
As shown in an alignment of the amino acid sequences of
the group III mGluR cytoplasmic C-terminal regions (Fig.
1A), one or more predicted consensus sites for PKC phos-
phorylation are present in all group III mGluR tail domains.
Notably, the serine residue corresponding to amino acid S862
in mGluR7A is conserved in all mGluRs with the exception of
the highly divergent mGluR4B sequence.
To determine which of the receptor tails can be phosphor-
ylated by PKC, we performed in vitro phosphorylation of all
group III mGluR tails fused to GST or MBP using PKM. As
shown in Fig. 1B, all fusion constructs except MBP-4B and
GST-6 were phosphorylated under the conditions used. These
phosphorylation events were mGluR tail-speci¢c, since neither
GST (Fig. 1B) nor MBP (not shown) displayed detectable 32P
incorporation under identical conditions. To elucidate which
of the four serines predicted to be phosphorylated in
mGluR7A (S862, S873, S877 and S881) are used in vitro,
mutants in which all or only three of the predicted serines
had been substituted by alanines (Fig. 2A) were also exam-
ined. Only wild-type GST-7A and the GST-7A-S234A mu-
tant, which still contains serine 862, were phosphorylated.
No 32P radioactivity was detected in the mutants GST-7A-
S1234A, GST-7A-S123A, GST-7A-S124A, and GST-7A-
S134A (Fig. 2B). When serine 862 was mutated to alanine
Fig. 1. A: Alignment of the C-terminal tail regions of group III mGluRs. The sequences shown include the following amino acid residues:
mGluR4A: 848^912; mGluR4B: 848^983; mGluR6: 840^871; mGluR7A: 851^916; mGluR7B: 851^923; mGluR8A: 844^908; and mGluR8B:
844^908. Two overlapping consensus sites for Ca2-dependent CaM binding are indicated: a 1-5-10 motif (- - -H- - -H- - - -H) and a 1-8-14 motif
(H- - - - - -H- - - - -H), where H indicates hydrophobic amino acid side chains. Predicted PKC phosphorylation sites are underlined. Serine residues
homologous to S862 in mGluR7A are marked with an asterisk. B: Phosphorylation of group III mGluR tails. Coomassie staining (left) and
32P incorporation revealed by autoradiography (right) are shown. GST and MBP fusion proteins of the C-tails of group III mGluRs were im-
mobilized on CaM-agarose and in vitro phosphorylated with PKM. Proteins were eluted with SDS sample bu¡er and analyzed by 12% SDS^
PAGE.
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(GST-7A-S862A) or its phosphorylation consensus sequence
was modi¢ed (GST-7A-EEE), PKM also failed to phosphor-
ylate the GST-7A C-terminal tail domain (Fig. 2B). This re-
sult indicates that serine 862 is the only residue in the
mGluR7A tail that is modi¢ed by PKC in vitro. Notably,
the homologous serine residue is not precisely conserved in
mGluR4B, consistent with the lack of phosphorylation seen
with the corresponding tail fusion protein (Fig. 1B). In
mGluR6, a serine predicted to be phosphorylated by PKC is
found at a position homologous to that of S862 in mGluR7A;
however, its C-terminally £anking residues di¡er signi¢cantly
from those found in the other group III mGluRs (Fig. 1A).
Secondary structure analysis predicts this variation to cause a
loss of K-helical content within this region (data not shown);
we propose this structural change to abolish recognition by
PKC.
In order to unravel whether phosphorylation of residue 862
in mGluR7A is su⁄cient to inhibit its interaction with CaM,
we mimicked phosphorylation of this amino acid by replacing
it by glutamate. CaM binding of the resulting mutant GST-
N25-S862E was strongly decreased as compared to the wild-
type GST-N25 fusion protein (Fig. 3A). To verify whether
S862 constitutes a residue important for CaM binding, we
replaced it by alanine (GST-N25-S862A). As shown in Fig.
3A, the binding of Ca2/CaM was not signi¢cantly a¡ected by
this mutation but comparable to binding to the wild-type
GST-N25 tail. In contrast, increasing the number of negative
charges by introducing three glutamates in the vicinity of S862
in mutant GST-7A-EEE completely abolished CaM binding
(Fig. 3A). A complete loss of CaM binding was also seen
when S862, T868, T871 and S873 in GST-N25 were replaced
by glutamate, or when replacing amino acids F863^V866 by
four glutamates (data not shown). Apparently, introduction
of negative charges in the N-terminal region of the mGluR7A
tail impairs CaM binding.
4. Discussion
Here, we demonstrate that PKC phosphorylates the cyto-
solic C-terminal regions of most group III mGluRs. All group
III mGluRs except mGluR4B display high homology (s 70%
identity) in the N-terminal portion of their cytosolic C-termi-
ni. In particular, the ¢rst 26 residues of the mGluR4A, -7 and
-8 tails are nearly identical (Fig. 1A). Divergence of mGluR4B
is due to a di¡erent splicing event as compared to the other
group III mGluR members [14,17,18]. Although all group III
mGluRs are predicted to be phosphorylated by PKC due to
the existence of one or multiple PKC phosphorylation con-
sensus sites ((S/T)-X-(K/R)) [19,20], only the tails sharing high
homology in their juxta-membrane region could be phosphor-
ylated in vitro. No 32P incorporation was detectable with the
mGluR4B or mGluR6 cytosolic domains. These results are
consistent with a potential in vivo regulation of CaM binding
to group III mGluR tails by PKC phosphorylation.
As only the serine residue corresponding to S862 in
mGluR7A is conserved in the homologous C-tails, we per-
formed additional experiments using alanine substitutions in
the mGluR7A tail region to examine the relevance of this
serine for PKC phosphorylation. Only mutants in which
S862 was not substituted showed 32P incorporation. Also, a
GST-7A-S862A construct was not phosphorylated, and muta-
tion of the consensus sequence for PKC phosphorylation
Fig. 2. A: A scheme illustrating the mutations introduced into the
mGluR7A tail region. The numbers in the ¢rst ¢ve constructs indi-
cate the four predicted phosphorylation sites S862, S873, S877 and
S881. In GST-7A-EEE, amino acids K864, A865 and V866 were re-
placed by glutamates. B: Phosphorylation of GST-7A mutants.
Phosphorylation of the wild-type GST-7A is shown in Fig. 1. Coo-
massie staining (top) and 32P incorporation revealed by autoradiog-
raphy (bottom) are shown. Fusion proteins were processed and in
vitro phosphorylated as described in the legend to Fig. 1.
Fig. 3. A: Ca2-dependent CaM binding of mGluR7A mutants. Fu-
sion proteins were immobilized on CaM-agarose in the presence of
either 2 mM CaCl2 or 5 mM EGTA. Bound material was eluted
with SDS sample bu¡er, analyzed on 12% SDS^PAGE and revealed
by Coomassie staining. Note the drastic reduction, or complete loss,
of CaM binding with GST-N25-S862E and GST-7A-EEE. The
bands marked with asterisks in the GST-7A and GST-7A-EEE lanes
represent the full-length proteins; the more rapidly migrating poly-
peptide species correspond to degradation products observed previ-
ously [6]. B: Amphipathic K-helical wheel projections demonstrating
loss of the amphipathic character of the putative CaM binding helix
(residues 860^872) upon glutamate substitutions.
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around residue 862 in GST-7A-EEE abolished serine modi¢-
cation. Thus, the serine residue adjacent to the seventh trans-
membrane region that is conserved in most group III mGluRs
constitutes their principal site of PKC phosphorylation.
S862 lies within a region of the mGluR7A C-terminal do-
main known to mediate Ca2/CaM binding [6], and PKC
phosphorylation of the mGluR7A tail has been found to pre-
vent the CaM interaction [15]. Notably, S862 is embedded
into positively charged amino acids interspersed among hy-
drophobic residues; such sequences have the potential to form
a helical amphipathic structure, with positive charges on one
side of the helix and hydrophobic ones on the other (Fig. 3B)
[21]. Such structures are characteristic for many Ca2/CaM
binding proteins. Ca2-dependent CaM interaction motifs
have been grouped into two major classes, designated motifs
1-8-14 and 1-5-10 [21]. Based on the di¡erent positions of
conserved hydrophobic residues, the ¢rst and last residues
of these motifs seem to be particularly important for CaM
binding. Most of the high-a⁄nity Ca2/CaM binding proteins
have a 1-8-14 motif, whose net charge varies from +3 to +6.
The net charge of the 1-5-10 motif, the other Ca2-dependent
CaM binding motif found in a number of proteins like CaM-
KII, MARCKS and synapsin, is only +2 to +3 [21,22]. All
mGluRs except mGluR6 contain both consensus motifs. In
fact, mGluR4A, -7A, -7B, -8A, and -8B possess a net charge
of +3, characteristic of the 1-5-10 motif, but not the high
value associated with the 1-8-14 motif (Figs. 1A and 3B).
PKC phosphorylation of the conserved serine is predicted to
reduce the net charge of the 1-5-10 motif. Indeed, mimicking
phosphorylation by replacing serine 862 with glutamate in
GST-7A-S862E reduced CaM binding drastically, whereas
alanine substitution in GST-7A-S862A showed no major ef-
fect. Also, introducing three consecutive negative charges into
the 1-5-10 motif by generating GST-7A-EEE completely abol-
ished CaM binding (Fig. 3A). This is consistent with the loss
of CaM binding resulting from neutralization of the positive
net charge of the amphipathic K-helix (Fig. 3B). Secondary
structure predictions indicate that the probability of residues
860^872 to form an K-helix is not altered in the mutants used
(data not shown). We therefore conclude that PKC phosphor-
ylation controls CaM binding by a simple electrostatic mech-
anism.
PKC activation has been shown to reduce inhibition of
forskolin-stimulated cAMP accumulation by group II and
group III mGluRs [23] and to regulate neurotransmission at
major synapses in the hippocampal formation [13]. These ¢nd-
ings suggest that PKC-induced inhibition of mGluR signaling
may be mediated by the inhibition of coupling of mGluRs to
G proteins. Such reduced coupling might re£ect an impaired
CaM regulation of GLQ-dependent group III mGluR signaling
[6]. However, a direct e¡ect of PKC phosphorylation on G
protein coupling to group III mGluRs remains to be demon-
strated.
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